IPO Alert Spotlight - Dragonfly Biosciences

IPO Alert Spotlight - Dragonfly Biosciences

ISSUER: Dragonfly Biosciences Ltd. (the “Company”)

  • Dragonfly Biosciences is an award-winning seed-to-shelf cannabidiol (CBD) manufacturer with blue chip UK retail clients including Boots, Sainsburys, Amazon UK, Superdrug, eBay and Harrods.
  • The Company owns the entire value chain from its certified organic farms, extraction facilities and state-of-the-art laboratories used for producing premium CBD products.
  • Dragonfly produces a cannabidiol or CBD, a cannabinoid that is extracted from the cannabis or hemp plant, but avoids the psychoactive cannabinoid known as THC, which is the staple of recreational and some medicinal cannabis.
  • CBD has been proven to have beneficial use against insomnia, anxiety and stress, and potentially chronic pain.
  • The Company also produces lotions which are intended for general skin care, repair, protection and moisturising.

MARKETED OFFERING:

  • Dragonfly Biosciences Ltd is looking to undertake an IPO on ASX to raise between $3 million and $5 million via the issue of between 15 million and 25 million shares at an offer price of $0.20. The company will have an indicative market capitalisation of approximately $37.9 million at maximum subscription on a fully diluted basis.
  • The company will also be offering one (1) free-attaching Option for every two (2) Shares subscribed for exercisable at $0.35 each on or before 31 December 2024.
  • Applications close 5pm AEST Thursday 3 August 2023.

For more information or to express interest please contact

https://www.asx.com.au/markets/company/drf

USE OF PROCEEDS:

The net proceeds from the Offering will be used by the Company for the exploration of the Company’s Drayton-Black Lake Project in northwestern Ontario and for working capital and general corporate purposes.

Key Objectives:

The Company’s main objectives are:

expand the product offering with existing UK retail distribution following the FSA accreditation and through

new product development;

  • expand UK retail partnerships to continue to position Dragonfly UK to be the number one CBD brand in the UK;
  • expand accreditation to include EU Food Standards Agency (EFSA), Australian Therapeutic Goods Administration (TGA) and the FDA (US) to establish Dragonfly as one of the few UK FSA, EFSA, TGA and FDA compliant brands;
  • expand the white label/wholesale business line leveraging the FSA, EFSA, TGA and FDA accreditations and thus capitalising on Dragonfly UK’s large-scale extraction facility;
  • leverage the Company’s existing distribution network to establish new retail partnerships in the USA and APAC region; and
  • build brand awareness in the key markets where Dragonfly CBD is distributed.

AGENTS:

Finexia: https://www.finexia.com.au/dragonfly.html

Online Application: https://apply.automic.com.au/DragonflyBiosciences

TMD: https://finexia.com.au/dragonfly-tmd

Prospectus: https://finexia.com.au/dragonfly-replacement-prosp...

DISCLAIMER:

This publication has been prepared for information purposes only. The source of information is Dragonfly Biosciences Ltd.’s prospectus dated June 27, 2022. This publication is neither a solicitation for the purchase of securities nor an offer of securities. You are expressly cautioned to seek the advice of a registered investment advisor and other professional advisors, as applicable, regarding the appropriateness of investing in Dragonfly Biosciences Ltd.’s securities. Any investment decision should be based on the prospectus and any supplemental or replacement prospectus to it. The statements in this publication are statements of fact and must not be interpreted as financial advice or a recommendation. This publication does not take into account your individual investment objectives, financial situation or particular needs.

The issuer of the securities is Dragonfly Biosciences Ltd. A prospectus in relation to the issuer’s offer is available and can be obtained https://finexia.com.au/dragonfly-replacement-prospe.... Offers for the securities will only be made in, or accompanied by, a copy of the prospectus. A person should consider the prospectus in deciding whether to acquire the securities. Anyone who wants to acquire the securities will need to complete the application form that will be in, or will accompany, the prospectus.


Please click here for more information

DRF:AU
The Conversation (0)
Court gavel in front of national flag of the USA having shadows of cannabis on wooden table.

DEA Submits Proposal to Reschedule Cannabis, Stocks Rally

The Associated Press reported Tuesday (April 30) that the US Drug Enforcement Administration (DEA) was on the cusp of rescheduling cannabis from a Schedule I substance, the same category as heroin and methamphetamines, to Schedule III.

The Department of Health and Human Services suggested cannabis be reclassified on August 29, 2023, and the DEA has been deliberating on the decision for months, urged by lawmakers to heed the recommendation.

According to the report, Attorney General Merrick Garland was scheduled to submit the proposal to the White House Office of Management and Budget on Tuesday afternoon. President Biden has been vocal about his stance on this issue and has urged the Attorney General to expedite the process, suggesting his readiness to move forward once the proposal reaches his desk.

Keep reading...Show less

Goodness Growth Provides CREAM & Fire Updates

Josh Rosen to shed Interim title and become Chief Executive Officer; Company provides other key personnel updates –

– Company receives a short-term extension of the maturity date on its credit facility –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Goodness Growth Holdings to Release First Quarter 2024 Results on May 7, 2024

Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced that it will release its financial results for its first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after the market closes.

Goodness Growth management will host a conference call with the investment community that day, Tuesday, May 7, 2024 at 4:30 p.m. ET (3:30 p.m. CT) to discuss its results. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET.

Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2024 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. to Hold 2024 First Quarter Earnings Conference Call on May 9, 2024

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.

To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations . To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company's website.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Cannabis Market Flourishes Amid Global Legalization, Driving Concerns About Road Safety

FinancialBuzz.com News Commentary

Over the past decade, the cannabis market has undergone significant expansion, driven largely by a wave of legalization efforts across the United States and other parts of the world. As state and national governments reassess their legal stance on cannabis, both for medical and recreational use, the industry has seen a surge in legitimacy and economic interest. In the United States, a majority of states have legalized cannabis in some form, reflecting a shift in public opinion and an acknowledgement of the potential medical benefits and revenue generation opportunities. Globally, countries like Canada, Uruguay, and several European nations have moved towards more liberal cannabis policies, further propelling the market's growth. The financial implications of these legalization efforts are substantial and continue to evolve. According to a report by Grand View Research, the global legal cannabis market size was valued at USD 13.2 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 25.5% from 2022 to 2030. Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO), Cronos Group Inc. (NASDAQ: CRON), Canopy Growth Corporation (NASDAQ: CGC), Aurora Cannabis Inc. (NASDAQ: ACB), Curaleaf Holdings, Inc. (OTC: CURLF)

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×